Literature DB >> 10947489

Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio.

A O'Hagan1, J W Stevens, J Montmartin.   

Abstract

The aim of this article is to consider Bayesian and frequentist inference methods for measures of incremental cost effectiveness in data obtained via a clinical trial. The most useful measure is the cost-effectiveness (C/E) acceptability curve. Recent publications on Bayesian estimation have assumed a normal posterior distribution, which ignores uncertainty in estimated variances, and suggest unnecessarily complicated methods of computation. We present a simple Bayesian computation for the C/E acceptability curve and a simple frequentist analogue. Our approach takes account of errors in estimated variances, resulting in calculations that are based on distributions rather than normal distributions. If inference is required about the C/E ratio, we argue that the standard frequentist procedures give unreliable or misleading inferences, and present instead a Bayesian interval.

Mesh:

Substances:

Year:  2000        PMID: 10947489     DOI: 10.2165/00019053-200017040-00004

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  19 in total

Review 1.  Statistical versus quantitative significance in the socioeconomic evaluation of medicines.

Authors:  B J O'Brien; M F Drummond
Journal:  Pharmacoeconomics       Date:  1994-05       Impact factor: 4.981

Review 2.  Statistical analysis in pharmacoeconomic studies. A review of current issues and standards.

Authors:  D Coyle
Journal:  Pharmacoeconomics       Date:  1996-06       Impact factor: 4.981

3.  The CE plane: a graphic representation of cost-effectiveness.

Authors:  W C Black
Journal:  Med Decis Making       Date:  1990 Jul-Sep       Impact factor: 2.583

Review 4.  Recommendations of the Panel on Cost-effectiveness in Health and Medicine.

Authors:  M C Weinstein; J E Siegel; M R Gold; M S Kamlet; L B Russell
Journal:  JAMA       Date:  1996-10-16       Impact factor: 56.272

5.  Problems with interval estimates of the incremental cost-effectiveness ratio.

Authors:  D F Heitjan; A J Moskowitz; W Whang
Journal:  Med Decis Making       Date:  1999 Jan-Mar       Impact factor: 2.583

6.  Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane.

Authors:  A Briggs; P Fenn
Journal:  Health Econ       Date:  1998-12       Impact factor: 3.046

7.  Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem.

Authors:  A R Willan; B J O'Brien
Journal:  Health Econ       Date:  1996 Jul-Aug       Impact factor: 3.046

8.  Statistical inference for cost-effectiveness ratios.

Authors:  E M Laska; M Meisner; C Siegel
Journal:  Health Econ       Date:  1997 May-Jun       Impact factor: 3.046

9.  Confidence intervals for cost/effectiveness ratios.

Authors:  P Wakker; M P Klaassen
Journal:  Health Econ       Date:  1995 Sep-Oct       Impact factor: 3.046

10.  Clinical importance, statistical significance and the assessment of economic and quality-of-life outcomes.

Authors:  M Drummond; B O'Brien
Journal:  Health Econ       Date:  1993-10       Impact factor: 3.046

View more
  19 in total

1.  The cost effectiveness of two new antiepileptic therapies in the absence of direct comparative data: a first approximation.

Authors:  Ben A van Hout; Dennis D Gagnon; Pauline McNulty; Anthony O'Hagan
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 2.  Advantages of using the net-benefit approach for analysing uncertainty in economic evaluation studies.

Authors:  Niklas Zethraeus; Magnus Johannesson; Bengt Jönsson; Mickael Löthgren; Magnus Tambour
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 3.  The contrast and convergence of Bayesian and frequentist statistical approaches in pharmacoeconomic analysis.

Authors:  Grant H Skrepnek
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

4.  Model-based economic evaluation for medical decision making: learn from the past and prepare for the future.

Authors:  Feng Xie
Journal:  J Thorac Dis       Date:  2013-06       Impact factor: 2.895

5.  NICE work: how NICE decides what we should pay for.

Authors:  John W Stevens
Journal:  Br J Gen Pract       Date:  2010-01       Impact factor: 5.386

6.  Presenting evidence and summary measures to best inform societal decisions when comparing multiple strategies.

Authors:  Simon Eckermann; Andrew R Willan
Journal:  Pharmacoeconomics       Date:  2011-07       Impact factor: 4.981

7.  Using Evidence from Randomised Controlled Trials in Economic Models: What Information is Relevant and is There a Minimum Amount of Sample Data Required to Make Decisions?

Authors:  John W Stevens
Journal:  Pharmacoeconomics       Date:  2018-10       Impact factor: 4.981

8.  Impact of small study bias on cost-effectiveness acceptability curves and value of information analyses.

Authors:  Dirk Müller; Eleanor Pullenayegum; Afschin Gandjour
Journal:  Eur J Health Econ       Date:  2014-05-20

9.  Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme.

Authors:  Janne A Martikainen; Akseli Kivioja; Taru Hallinen; Pia Vihinen
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

10.  Bayesian decision analysis for choosing between diagnostic/prognostic prediction procedures.

Authors:  John Kornak; Ying Lu
Journal:  Stat Interface       Date:  2011       Impact factor: 0.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.